Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afuresertib + sintilimab + taxane in PD-1/PD-L1–resistant solid tumors
CTR20220746Phase 2Completed
- Sponsor
- Laekna
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afuresertib in Cervical Cancer (CC), endometrial cancer (EC), Esophageal Squamous Cell Carcinoma (ESCC) and 4 more, sponsored by Laekna. Started Apr 2022; status: completed.
02
Drugs
afuresertib
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)Esophageal Squamous Cell Carcinoma (ESCC)esophageal cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220746.